Parkinson’s Disease

Latest News

Serum 25(OH)D as a Biomarker for Cognitive Impairment in Parkinson Disease

By

Jessica Nye, PhD

Researchers sought to assess the relationship between serum 25(OH)D levels and cognition in patients with Parkinson disease.

NDA Submitted for Continuous SC Infusion Therapy for Parkinson Disease

By

Brian Park, PharmD

ABBV-951 is a solution of levodopa and carbidopa prodrugs for continuous subcutaneous infusion.

Parkinson Disease Psychosis Tied to Higher Risk for All-Cause Mortality

By

Brandon May

Presenting at the 2022 AAN Annual Meeting, Mayo Clinic researchers investigated and compared the survival rates and symptoms of Parkinson disease and Parkinson disease psychosis.

Pimavanserin Also Treats Hallucinations, Delusions in Parkinson Disease Dementia

By

Mary Beth Maslowski

Presenting at the 2022 AAN Annual Meeting, researchers examined pimavanserin for the treatment of dementia-related psychosis.

GBA Variants Impact Cognitive Status in Amyotrophic Lateral Sclerosis

By

Brandon May

Researchers sought to determine the effect GBA variants have on cognitive status in patients with amyotrophic lateral sclerosis.

Stress and Stress Susceptibility Effects on the Motor Cortex and its Function

By

Jessica Nye, PhD

Male mice were exposed to chronic stress using a social defeat stress experiment. Mice were assessed for behavioral deviations and impacts to motor learning after the stress experiment as well as neural changes due to stress.

Revision of the Sporadic Creutzfeldt-Jakob Disease International Surveillance Network Diagnostic Criteria

By

Jessica Nye, PhD

All individuals in the study who died between 2017 and 2019 due to sporadic Creutzfeldt-Jakob disease (sCJD) and controls who had alternative neuropathological diagnoses were assessed for sCJD using the original and revised diagnostic criteria.

Binding of L-DOPA With Siderocalin Through Iron-Siderophore: Implications for Parkinson Disease

By

Jessica Nye, PhD

L-DOPA is the frontline therapy for patients with PD, however, as the disease progresses, patients require higher and more frequent dosing. In order to better understand the binding affinity of L-DOPA and associated metabolites, binding affinity and surface plasmon resonance experiments were performed.

People With Parkinson Disease May Have Lower Oral Health Quality of Life

By

Heather R. Johnson

Authors of this study collected data between June 2020 and June 2021 using a 3-part electronic questionnaire oral health quality of life in those with Parkinson disease.

Functionally Scored Carbidopa/Levodopa Tablet Now Available for Parkinson Disease

By

Brian Park, PharmD

The FDA approved Dhivy in November 2021 based upon bioavailability studies comparing Dhivy to an immediate-release tablet containing 25mg of carbidopa and 100mg of levodopa.